BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vinhas R, Mendes R, Fernandes AR, Baptista PV. Nanoparticles-Emerging Potential for Managing Leukemia and Lymphoma. Front Bioeng Biotechnol. 2017;5:79. [PMID: 29326927 DOI: 10.3389/fbioe.2017.00079] [Cited by in Crossref: 20] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 De Marco I. Supercritical Fluids and Nanoparticles in Cancer Therapy. Micromachines 2022;13:1449. [DOI: 10.3390/mi13091449] [Reference Citation Analysis]
2 Liang H, Zou F, Fu L, Liu Q, Wang B, Liang X, Liu J, Liu Q. PEG-Bottlebrush Stabilizer-Based Worm-like Nanocrystal Micelles with Long-Circulating and Controlled Release for Delivery of a BCR-ABL Inhibitor against Chronic Myeloid Leukemia (CML). Pharmaceutics 2022;14:1662. [DOI: 10.3390/pharmaceutics14081662] [Reference Citation Analysis]
3 de Oliveira TV, de Oliveira RS, Dos Santos J, Funk NL, Petzhold CL, Beck RCR. Redispersible 3D printed nanomedicines: An original application of the semisolid extrusion technique. Int J Pharm 2022;624:122029. [PMID: 35853566 DOI: 10.1016/j.ijpharm.2022.122029] [Reference Citation Analysis]
4 Hamimed S, Jabberi M, Chatti A. Nanotechnology in drug and gene delivery. Naunyn Schmiedebergs Arch Pharmacol 2022;395:769-87. [PMID: 35505234 DOI: 10.1007/s00210-022-02245-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Mahajan S, Aalhate M, Guru SK, Singh PK. Nanomedicine as a magic bullet for combating lymphoma. J Control Release 2022;347:211-36. [PMID: 35533946 DOI: 10.1016/j.jconrel.2022.05.002] [Reference Citation Analysis]
6 Jia S, Guo B, Wang L, Peng L, Zhang L. The Current Status of SSRP1 in Cancer: Tribulation and Road Ahead. J Healthc Eng 2022;2022:3528786. [PMID: 35463672 DOI: 10.1155/2022/3528786] [Reference Citation Analysis]
7 Zoulikha M, He W. Targeted Drug Delivery for Chronic Lymphocytic Leukemia. Pharm Res. [DOI: 10.1007/s11095-022-03214-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Jiang Y, Lin W, Zhu L. Targeted Drug Delivery for the Treatment of Blood Cancers. Molecules 2022;27:1310. [PMID: 35209102 DOI: 10.3390/molecules27041310] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Liu A, Li B, Yang M, Shi Y, Su J. Targeted treprostinil delivery inhibits pulmonary arterial remodeling. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2021.174700] [Reference Citation Analysis]
10 Kemp JA, Kwon YJ. Cancer nanotechnology: current status and perspectives. Nano Converg 2021;8:34. [PMID: 34727233 DOI: 10.1186/s40580-021-00282-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
11 Singh V, Sahebkar A, Kesharwani P. Poly (propylene imine) dendrimer as an emerging polymeric nanocarrier for anticancer drug and gene delivery. European Polymer Journal 2021;158:110683. [DOI: 10.1016/j.eurpolymj.2021.110683] [Cited by in Crossref: 8] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
12 Allahyari SE, Hajizadeh F, Zekiy AO, Mansouri N, Gilan PS, Mousavi SM, Masjedi A, Hassannia H, Ahmadi M, Mohammadi H, Yousefi M, Izadi S, Zolbanin NM, Jafari R, Jadidi-Niaragh F. Simultaneous inhibition of CD73 and IL-6 molecules by siRNA-loaded nanoparticles prevents the growth and spread of cancer. Nanomedicine 2021;34:102384. [PMID: 33771704 DOI: 10.1016/j.nano.2021.102384] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Mosteo L, Storer J, Batta K, Searle EJ, Duarte D, Wiseman DH. The Dynamic Interface Between the Bone Marrow Vascular Niche and Hematopoietic Stem Cells in Myeloid Malignancy. Front Cell Dev Biol 2021;9:635189. [PMID: 33777944 DOI: 10.3389/fcell.2021.635189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
14 Esmaeili S, Pourbagheri-sigaroodi A, Yousefi A, Fakhroueian Z, Momeny M, Bashash D. ZnO Q-Dots-Induced Apoptosis Was Coupled with the Induction of PPARγ in Acute Promyelocytic Leukemia Cells; Proposing a Novel Application of Nanoparticles in Combination with Pioglitazone. J Clust Sci 2022;33:579-91. [DOI: 10.1007/s10876-021-01992-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Hejmady S, Pradhan R, Alexander A, Agrawal M, Singhvi G, Gorain B, Tiwari S, Kesharwani P, Dubey SK. Recent advances in targeted nanomedicine as promising antitumor therapeutics. Drug Discovery Today 2020;25:2227-44. [DOI: 10.1016/j.drudis.2020.09.031] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
16 Wan Z, Sun R, Moharil P, Chen J, Liu Y, Song X, Ao Q. Research advances in nanomedicine, immunotherapy, and combination therapy for leukemia. J Leukoc Biol 2021;109:425-36. [PMID: 33259068 DOI: 10.1002/JLB.5MR0620-063RR] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
17 Fan C, Joshi J, Li F, Xu B, Khan M, Yang J, Zhu W. Nanoparticle-Mediated Drug Delivery for Treatment of Ischemic Heart Disease. Front Bioeng Biotechnol 2020;8:687. [PMID: 32671049 DOI: 10.3389/fbioe.2020.00687] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
18 Szczepanek J. Role of microRNA dysregulation in childhood acute leukemias: Diagnostics, monitoring and therapeutics: A comprehensive review. World J Clin Oncol 2020; 11(6): 348-369 [PMID: 32855905 DOI: 10.5306/wjco.v11.i6.348] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
19 Huang L, Huang J, Huang J, Xue H, Liang Z, Wu J, Chen C. Nanomedicine - a promising therapy for hematological malignancies. Biomater Sci 2020;8:2376-93. [PMID: 32314759 DOI: 10.1039/d0bm00129e] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
20 Falgàs A, Pallarès V, Serna N, Sánchez-García L, Sierra J, Gallardo A, Alba-Castellón L, Álamo P, Unzueta U, Villaverde A, Vázquez E, Mangues R, Casanova I. Selective delivery of T22-PE24-H6 to CXCR4+ diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model. Theranostics 2020;10:5169-80. [PMID: 32373205 DOI: 10.7150/thno.43231] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
21 Wong XY, Sena-Torralba A, Álvarez-Diduk R, Muthoosamy K, Merkoçi A. Nanomaterials for Nanotheranostics: Tuning Their Properties According to Disease Needs. ACS Nano 2020;14:2585-627. [PMID: 32031781 DOI: 10.1021/acsnano.9b08133] [Cited by in Crossref: 124] [Cited by in F6Publishing: 89] [Article Influence: 62.0] [Reference Citation Analysis]
22 Roma-Rodrigues C, Rivas-García L, Baptista PV, Fernandes AR. Gene Therapy in Cancer Treatment: Why Go Nano? Pharmaceutics 2020;12:E233. [PMID: 32151052 DOI: 10.3390/pharmaceutics12030233] [Cited by in Crossref: 29] [Cited by in F6Publishing: 58] [Article Influence: 14.5] [Reference Citation Analysis]
23 Houshmand M, Garello F, Circosta P, Stefania R, Aime S, Saglio G, Giachino C. Nanocarriers as Magic Bullets in the Treatment of Leukemia. Nanomaterials (Basel) 2020;10:E276. [PMID: 32041219 DOI: 10.3390/nano10020276] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
24 Misra R, Kandoi S, Varadaraj S, Vijayalakshmi S, Nanda A, Verma RS. Nanotheranostics: A tactic for cancer stem cells prognosis and management. Journal of Drug Delivery Science and Technology 2020;55:101457. [DOI: 10.1016/j.jddst.2019.101457] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
25 Roma-Rodrigues C, Fernandes AR, Baptista PV. Counteracting the effect of leukemia exosomes by antiangiogenic gold nanoparticles. Int J Nanomedicine 2019;14:6843-54. [PMID: 31692567 DOI: 10.2147/IJN.S215711] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
26 Reis CA, Rodrigues CF, Moreira AF, Jacinto TA, Ferreira P, Correia IJ. Development of gold-core silica shell nanospheres coated with poly-2-ethyl-oxazoline and β-cyclodextrin aimed for cancer therapy. Materials Science and Engineering: C 2019;98:960-8. [DOI: 10.1016/j.msec.2019.01.068] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
27 DuRoss AN, Neufeld MJ, Rana S, Thomas CR Jr, Sun C. Integrating nanomedicine into clinical radiotherapy regimens. Adv Drug Deliv Rev 2019;144:35-56. [PMID: 31279729 DOI: 10.1016/j.addr.2019.07.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
28 Ghosh S, Lalani R, Patel V, Bardoliwala D, Maiti K, Banerjee S, Bhowmick S, Misra A. Combinatorial nanocarriers against drug resistance in hematological cancers: Opportunities and emerging strategies. Journal of Controlled Release 2019;296:114-39. [DOI: 10.1016/j.jconrel.2019.01.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]